000			01407 a2200373 4500
005			20250513200225.0
264		0	_c20000128
008			200001s 0 0 eng d
022			_a0378-5122
024	7		_a10.1016/s0378-5122(99)00053-5 _2doi
040			_aNLM _beng _cNLM
100	1		_aWolfe, B M
245	0	0	_aImpact on postmenopausal symptoms of adding continuous C-21 versus C-19 progestin to estrogen. _h[electronic resource]
260			_bMaturitas _cOct 1999
300			_a153-61 p. _bdigital
500			_aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdverse Drug Reaction Reporting Systems
650	0	4	_aClimacteric _xdrug effects
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDouble-Blind Method
650	0	4	_aDrug Administration Schedule
650	0	4	_aDrug Therapy, Combination
650	0	4	_aEstrogen Replacement Therapy
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aMedroxyprogesterone Acetate _xadministration & dosage
650	0	4	_aMiddle Aged
650	0	4	_aNorgestrel _xadministration & dosage
650	0	4	_aProspective Studies
700	1		_aKoval, J J
700	1		_aNisker, J A
773	0		_tMaturitas _gvol. 33 _gno. 2 _gp. 153-61
856	4	0	_uhttps://doi.org/10.1016/s0378-5122(99)00053-5 _zAvailable from publisher's website
999			_c10553952 _d10553952